JP2025504278A5 - - Google Patents

Info

Publication number
JP2025504278A5
JP2025504278A5 JP2024530469A JP2024530469A JP2025504278A5 JP 2025504278 A5 JP2025504278 A5 JP 2025504278A5 JP 2024530469 A JP2024530469 A JP 2024530469A JP 2024530469 A JP2024530469 A JP 2024530469A JP 2025504278 A5 JP2025504278 A5 JP 2025504278A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
antibody
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/034872 external-priority patent/WO2024081274A1/en
Publication of JP2025504278A publication Critical patent/JP2025504278A/ja
Publication of JP2025504278A5 publication Critical patent/JP2025504278A5/ja
Pending legal-status Critical Current

Links

JP2024530469A 2022-10-12 2023-10-11 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法 Pending JP2025504278A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263415526P 2022-10-12 2022-10-12
US63/415,526 2022-10-12
US202263415928P 2022-10-13 2022-10-13
US63/415,928 2022-10-13
US202363449478P 2023-03-02 2023-03-02
US63/449,478 2023-03-02
PCT/US2023/034872 WO2024081274A1 (en) 2022-10-12 2023-10-11 Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (2)

Publication Number Publication Date
JP2025504278A JP2025504278A (ja) 2025-02-12
JP2025504278A5 true JP2025504278A5 (enExample) 2025-03-18

Family

ID=90670011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530469A Pending JP2025504278A (ja) 2022-10-12 2023-10-11 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20240150467A1 (enExample)
EP (1) EP4601693A1 (enExample)
JP (1) JP2025504278A (enExample)
KR (1) KR20250084959A (enExample)
CN (1) CN120265320A (enExample)
AU (1) AU2023361390A1 (enExample)
CL (2) CL2025001101A1 (enExample)
CO (1) CO2025004617A2 (enExample)
IL (1) IL320229A (enExample)
MX (1) MX2025004328A (enExample)
TW (3) TWI887800B (enExample)
WO (1) WO2024081274A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
MX2022014734A (es) * 2020-05-26 2023-03-15 Regeneron Pharma Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
JP2023545926A (ja) * 2020-09-24 2023-11-01 メルク・シャープ・アンド・ドーム・エルエルシー プログラム死受容体１（ｐｄ－１）抗体とヒアルロニダーゼ変異体とそれらのフラグメントとの安定製剤およびその使用方法
MX2023004847A (es) * 2020-10-28 2023-07-11 Ikena Oncology Inc Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.
US20220233693A1 (en) * 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
JP2024501029A (ja) * 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与

Similar Documents

Publication Publication Date Title
Ducreux et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
JP2025020147A5 (enExample)
Kouroussis et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
JP2022544280A5 (enExample)
JP2023546009A5 (enExample)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2020536887A5 (enExample)
JP2022527334A5 (enExample)
JP2025504278A5 (enExample)
JP2021530502A5 (enExample)
Chen et al. Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non–small-cell lung cancer
CN115461079A (zh) 用于治疗肾癌的联用药物
Sun et al. Phase II study of S-1 plus cisplatin as first-line therapy in patients with metastatic esophageal carcinoma
JP2024513247A5 (enExample)
WO2011090005A1 (ja) 大腸癌の治療用医薬および治療方法
JP2021529777A5 (enExample)
Fujitani et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer
JP2021523096A5 (enExample)
Choi et al. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding
IL320229A (en) Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
Katakami et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB–IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
Obarevich et al. Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)
TW201929900A (zh) Ｐｄ－１抗體和阿帕替尼聯合治療三陰性乳腺癌的用途
JP2024536201A5 (enExample)